-DOCSTART-	
	
Multiple	B-Process
respiratory	I-Process
chain	I-Process
deficiencies	I-Process
represent	O
a	O
common	O
cause	O
of	O
mitochondrial	B-Process
diseases	I-Process
and	O
are	O
associated	O
with	O
a	B-Data
wide	I-Data
range	I-Data
of	I-Data
clinical	I-Data
symptoms	I-Data
.	O
	
We	O
report	O
a	B-Material
subject	I-Material
,	O
born	O
to	O
consanguineous	B-Material
parents	I-Material
,	O
with	O
growth	B-Process
retardation	I-Process
and	O
neurological	B-Process
deterioration	I-Process
.	O
	
Multiple	B-Process
respiratory	I-Process
chain	I-Process
deficiency	I-Process
was	O
found	O
in	O
muscle	B-Material
and	I-Material
fibroblasts	I-Material
of	I-Material
the	I-Material
subject	I-Material
as	O
well	O
as	O
abnormal	B-Material
assembly	I-Material
of	I-Material
complexes	I-Material
I	I-Material
and	I-Material
IV	I-Material
.	O
	
A	B-Method
microsatellite	I-Method
genotyping	I-Method
of	O
the	B-Material
family	I-Material
members	I-Material
detected	O
only	O
one	O
region	O
of	O
homozygosity	B-Process
on	O
chromosome	B-Material
17q24.2-q25.3	I-Material
in	O
which	O
we	O
focused	O
our	O
attention	O
to	O
genes	B-Material
involved	O
in	O
mitochondrial	B-Process
translation	I-Process
.	O
	
We	O
sequenced	B-Process
MRPL12	B-Material
,	O
encoding	O
the	B-Material
mitochondrial	I-Material
ribosomal	I-Material
protein	I-Material
L12	I-Material
and	O
identified	O
a	B-Process
c.542C	I-Process
>	I-Process
T	I-Process
transition	I-Process
in	O
exon	B-Material
5	I-Material
changing	O
a	B-Material
highly	I-Material
conserved	I-Material
alanine	I-Material
into	O
a	B-Material
valine	I-Material
(	I-Material
p	I-Material
.	I-Material
Ala181Val	I-Material
)	I-Material
.	O
	
This	B-Process
mutation	I-Process
resulted	O
in	O
a	B-Data
decreased	I-Data
steady	I-Data
-	I-Data
state	I-Data
level	I-Data
of	O
MRPL12	B-Material
protein	I-Material
,	O
with	O
altered	B-Process
integration	I-Process
into	O
the	B-Material
large	I-Material
ribosomal	I-Material
subunit	I-Material
.	O
	
Moreover	O
,	O
an	B-Data
overall	I-Data
mitochondrial	I-Data
translation	I-Data
defect	I-Data
was	O
observed	O
in	O
the	B-Material
subject	I-Material
's	I-Material
fibroblasts	I-Material
with	O
a	B-Process
significant	I-Process
reduction	I-Process
of	I-Process
synthesis	I-Process
of	O
COXI	B-Material
,	I-Material
COXII	I-Material
and	I-Material
COXIII	I-Material
subunits	I-Material
.	O
	
Modeling	B-Process
of	O
MRPL12	B-Material
shows	O
Ala181	B-Material
positioned	O
in	O
a	B-Material
helix	I-Material
potentially	O
involved	O
in	O
an	B-Process
interface	I-Process
of	I-Process
interaction	I-Process
suggesting	O
that	O
the	B-Process
p	I-Process
.	I-Process
Ala181Val	I-Process
change	I-Process
might	O
be	O
predicted	O
to	O
alter	B-Process
interactions	I-Process
with	O
the	B-Data
elongation	I-Data
factors	I-Data
.	O
	
These	O
results	O
contrast	O
with	O
the	B-Material
eubacterial	I-Material
orthologues	I-Material
of	I-Material
human	I-Material
MRPL12	I-Material
,	O
	
where	O
L7/L12	B-Material
proteins	I-Material
do	O
not	O
appear	O
to	O
have	O
a	B-Process
selective	I-Process
effect	I-Process
on	O
translation	B-Process
.	O
	
Therefore	O
,	O
analysis	O
of	O
the	B-Material
mutated	I-Material
version	I-Material
found	O
in	O
the	B-Material
subject	I-Material
presented	O
here	O
suggests	O
that	O
the	B-Material
mammalian	I-Material
protein	I-Material
does	O
not	O
function	O
in	O
an	O
entirely	O
analogous	O
manner	O
to	O
the	B-Material
eubacterial	I-Material
	
L7/L12	I-Material
equivalent	I-Material
.	O
	
Highlights	O
•	O
	
MRPL12	B-Process
function	I-Process
is	O
not	O
entirely	O
analogous	O
to	O
the	B-Material
eubacterial	I-Material
	
L7/L12	I-Material
equivalent	I-Material
.	O
	
•	O
	
Mutations	B-Process
in	O
MRPL12	B-Material
cause	O
translation	B-Process
defects	I-Process
.	O
	
•	O
	
Mutations	B-Process
in	O
apparently	O
universal	B-Data
translation	I-Data
factors	I-Data
can	O
affect	O
different	B-Material
OXPHOS	I-Material
complexes	I-Material
.	O
	
-DOCSTART-	
	
Background	O
	
Previous	O
research	O
has	O
suggested	O
that	O
a	B-Data
substantial	I-Data
proportion	I-Data
of	O
the	B-Material
population	I-Material
are	O
severely	B-Process
affected	I-Process
by	O
tinnitus	B-Process
,	O
however	O
recent	B-Data
population	I-Data
data	I-Data
are	O
lacking	O
.	O
	
Furthermore	O
,	O
there	O
is	O
growing	B-Data
evidence	I-Data
that	O
the	B-Process
perception	I-Process
of	I-Process
severity	I-Process
is	O
closely	O
related	O
to	O
personality	B-Data
factors	I-Data
such	O
as	O
neuroticism	B-Process
.	O
	
Objective	O
	
In	O
a	B-Data
subset	I-Data
(	I-Data
N=172,621	I-Data
)	I-Data
of	O
a	B-Material
large	I-Material
population	I-Material
sample	I-Material
of	O
>	B-Data
500,000	I-Data
adults	B-Material
aged	B-Data
40	I-Data
to	I-Data
69years	I-Data
,	O
(	O
from	O
the	B-Material
UK	I-Material
Biobank	I-Material
dataset	I-Material
)	O
we	O
calculated	B-Process
the	B-Data
prevalence	I-Data
of	O
tinnitus	B-Process
and	O
that	O
which	O
is	O
perceived	O
as	O
bothersome	O
,	O
and	O
examined	O
the	B-Process
association	I-Process
between	O
tinnitus	B-Process
and	O
a	B-Process
putative	I-Process
predisposing	I-Process
personality	I-Process
factor	I-Process
,	I-Process
neuroticism	I-Process
.	O
	
Method	O
Participants	B-Material
were	O
recruited	O
through	O
National	B-Data
Health	I-Data
Service	I-Data
registers	I-Data
and	O
aimed	O
to	O
be	O
inclusive	O
and	O
as	O
representative	O
of	O
the	B-Material
UK	I-Material
population	I-Material
as	O
possible	O
.	O
	
The	B-Process
assessment	I-Process
included	O
subjective	B-Material
questions	I-Material
concerning	O
hearing	B-Process
and	O
tinnitus	B-Process
.	O
	
Neuroticism	B-Process
was	O
self	B-Method
-	I-Method
rated	I-Method
on	O
13	B-Material
questions	I-Material
from	O
the	B-Material
Eysenck	I-Material
Personality	I-Material
Inventory	I-Material
.	O
	
Associations	B-Data
between	O
neuroticism	B-Process
and	O
tinnitus	B-Process
were	O
tested	O
with	O
logistic	B-Method
regression	I-Method
analyses	I-Method
.	O
	
Results	O
Prevalence	B-Process
of	I-Process
tinnitus	I-Process
was	O
significantly	O
higher	O
for	O
males	B-Material
,	O
and	O
increased	O
with	O
age	B-Data
,	O
doubling	B-Process
between	O
the	B-Material
youngest	I-Material
and	I-Material
oldest	I-Material
age	I-Material
groups	I-Material
(	O
males	B-Data
13	I-Data
%	I-Data
and	I-Data
26	I-Data
%	I-Data
;	I-Data
females	I-Data
9	I-Data
%	I-Data
and	I-Data
19	I-Data
%	I-Data
respectively	O
)	O
.	O
	
Of	O
those	O
with	O
tinnitus	B-Process
,	O
females	B-Material
were	O
more	O
likely	O
to	O
report	O
bothersome	B-Process
tinnitus	I-Process
.	O
	
Neuroticism	B-Process
was	O
associated	O
with	O
current	B-Process
tinnitus	I-Process
and	O
bothersome	B-Process
tinnitus	I-Process
,	O
with	O
the	B-Data
items	I-Data
:	O
'	B-Data
loneliness	I-Data
'	I-Data
,	O
'	B-Data
mood	I-Data
swings	I-Data
'	I-Data
,	O
'	B-Data
worrier	I-Data
/	I-Data
anxious	I-Data
'	I-Data
and	O
'	B-Data
miserableness	I-Data
'	I-Data
,	O
as	O
the	O
strongest	O
associations	O
of	O
bothersome	B-Process
tinnitus	I-Process
.	O
	
Conclusions	O
Neuroticism	B-Process
was	O
identified	B-Process
as	O
a	B-Data
novel	I-Data
association	I-Data
with	O
tinnitus	B-Process
.	O
	
Individuals	B-Material
with	O
tinnitus	B-Process
and	O
higher	B-Data
levels	I-Data
of	O
neuroticism	B-Process
are	O
more	O
likely	O
to	O
experience	O
bothersome	B-Process
tinnitus	I-Process
,	O
possibly	O
as	O
a	O
reflection	O
of	O
greater	B-Data
sensitivity	I-Data
to	O
intrusive	B-Process
experiences	I-Process
.	O
	
-DOCSTART-	
	
Phialemonium	B-Process
infection	I-Process
in	O
humans	B-Material
is	O
rare	B-Data
.	O
	
We	O
report	O
a	B-Material
7-year	I-Material
-	I-Material
old	I-Material
healthy	I-Material
boy	I-Material
who	O
presented	O
with	O
chronic	B-Process
otorrhea	I-Process
,	O
which	O
persisted	O
despite	O
adequate	B-Process
antibiotic	I-Process
therapy	I-Process
and	O
four	B-Data
preservative	B-Process
tympanomastoidectomy	I-Process
operations	I-Process
.	O
	
Following	O
3	O
years	O
of	O
intermittent	B-Process
topical	I-Process
antibiotic	I-Process
therapy	I-Process
,	O
cultures	B-Material
eventually	O
grew	B-Process
Phialemonium	B-Material
,	O
which	O
necessitated	O
a	B-Method
more	I-Method
extensive	I-Method
operation	I-Method
,	O
combined	O
with	O
systemic	B-Material
/	I-Material
topical	I-Material
anti	I-Material
-	I-Material
fungal	I-Material
agent	I-Material
to	O
achieve	O
clinical	B-Process
cure	I-Process
.	O
	
-DOCSTART-	
	
BACKGROUND	O
:	O
	
Common	B-Process
etiology	I-Process
of	O
vascular	B-Process
diseases	I-Process
and	O
later	B-Process
-	I-Process
life	I-Process
depression	I-Process
may	O
provide	O
important	B-Data
synergies	I-Data
for	O
prevention	B-Process
.	O
	
We	O
examined	O
whether	O
standard	B-Data
clinical	I-Data
risk	I-Data
profiles	I-Data
developed	O
for	O
vascular	B-Process
diseases	I-Process
also	O
predict	B-Process
depressive	B-Data
symptoms	I-Data
in	O
older	B-Material
adults	I-Material
.	O
	
METHODS	O
:	O
	
Data	O
were	O
drawn	O
from	O
the	B-Method
Whitehall	I-Method
II	I-Method
study	I-Method
with	O
baseline	B-Process
examination	I-Process
in	O
1991	B-Data
;	O
follow	B-Process
-	I-Process
up	I-Process
screenings	I-Process
in	O
1997	B-Data
,	I-Data
2003	I-Data
,	I-Data
and	I-Data
2008	I-Data
;	O
and	O
additional	B-Process
disease	I-Process
ascertainment	I-Process
from	O
hospital	B-Material
data	I-Material
and	O
registry	B-Material
linkage	I-Material
on	O
5318	B-Material
participants	I-Material
(	O
mean	B-Data
age	I-Data
54.8	I-Data
years	I-Data
,	I-Data
31	I-Data
%	I-Data
women	I-Data
)	O
without	O
depressive	B-Data
symptoms	I-Data
at	O
baseline	B-Data
.	O
	
Vascular	B-Data
risk	I-Data
was	O
assessed	B-Process
with	O
the	B-Data
Framingham	I-Data
Cardiovascular	I-Data
,	I-Data
Coronary	I-Data
Heart	I-Data
Disease	I-Data
,	I-Data
and	I-Data
Stroke	I-Data
Risk	I-Data
Scores	I-Data
.	O
	
New	B-Data
depressive	I-Data
symptoms	I-Data
at	O
each	B-Process
follow	I-Process
-	I-Process
up	I-Process
screening	I-Process
were	O
identified	O
by	O
General	B-Method
Health	I-Method
Questionnaire	I-Method
caseness	I-Method
,	O
a	B-Method
Center	I-Method
for	I-Method
Epidemiologic	I-Method
Studies	I-Method
Depression	I-Method
Scale	I-Method
score	B-Data
≥16	I-Data
,	O
and	O
use	O
of	O
antidepressant	B-Material
medication	I-Material
.	O
	
RESULTS	O
:	O
	
Diagnosed	B-Process
vascular	I-Process
disease	I-Process
(	O
that	O
is	O
,	O
coronary	B-Process
heart	I-Process
disease	I-Process
or	I-Process
stroke	I-Process
)	O
was	O
associated	O
with	O
an	B-Data
increased	I-Data
risk	I-Data
for	O
depressive	B-Process
symptoms	I-Process
,	O
age-	B-Data
and	I-Data
sex	I-Data
-	I-Data
adjusted	I-Data
odds	I-Data
ratios	I-Data
from	I-Data
1.5	I-Data
(	I-Data
95	I-Data
%	I-Data
confidence	I-Data
interval	I-Data
1.0	I-Data
-	I-Data
2.2	I-Data
)	I-Data
to	I-Data
2.0	I-Data
(	I-Data
1.4	I-Data
-	I-Data
3.0	I-Data
)	I-Data
,	O
depending	O
on	O
the	B-Data
indicator	I-Data
of	O
depressive	B-Data
symptoms	I-Data
.	O
	
Among	O
participants	B-Material
without	O
manifest	B-Process
vascular	I-Process
disease	I-Process
,	O
the	B-Data
Stroke	I-Data
Risk	I-Data
Score	I-Data
was	O
associated	O
with	O
Center	B-Method
for	I-Method
Epidemiologic	I-Method
Studies	I-Method
Depression	I-Method
Scale	I-Method
depressive	B-Data
symptoms	I-Data
before	I-Data
age	I-Data
65	I-Data
(	O
age-	B-Data
and	I-Data
sex	I-Data
-	I-Data
adjusted	I-Data
odds	I-Data
ratio	I-Data
per	I-Data
10	I-Data
%	I-Data
absolute	I-Data
change	I-Data
in	I-Data
the	I-Data
score	I-Data
=	I-Data
3.1	I-Data
[	I-Data
1.5	I-Data
-	I-Data
6.5	I-Data
]	I-Data
)	O
,	O
but	O
none	O
of	O
the	B-Data
risk	I-Data
scores	I-Data
predicted	O
new	B-Data
-	I-Data
onset	I-Data
depressive	I-Data
symptoms	I-Data
in	O
those	B-Material
	
aged	I-Material
≥65	I-Material
(	O
odds	B-Data
ratios	I-Data
from	I-Data
.8	I-Data
to	I-Data
1.2	I-Data
)	O
.	O
	
CONCLUSIONS	O
	
:	O
These	O
data	O
suggest	O
that	O
public	B-Process
health	I-Process
measures	I-Process
to	O
improve	B-Process
vascular	B-Data
risk	I-Data
status	I-Data
will	O
influence	O
the	O
incidence	O
of	O
later	B-Data
-	I-Data
life	I-Data
depressive	I-Data
symptoms	I-Data
via	O
reduced	B-Data
rates	I-Data
of	O
manifest	B-Process
vascular	I-Process
disease	I-Process
.	O
	
-DOCSTART-	
	
Objective	O
Otitis	B-Process
media	I-Process
with	I-Process
effusion	I-Process
(	I-Process
OME	I-Process
)	I-Process
,	O
a	B-Process
common	I-Process
chronic	I-Process
childhood	I-Process
condition	I-Process
affecting	I-Process
hearing	I-Process
,	O
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
bacterial	B-Process
infection	I-Process
,	O
with	O
biofilms	B-Material
recently	O
implicated	O
.	O
	
Although	O
bacterial	B-Material
DNA	I-Material
can	O
be	O
detected	B-Process
by	O
polymerase	B-Process
chain	I-Process
reaction	I-Process
in	O
80	B-Data
%	I-Data
of	O
patients	B-Material
,	O
typically	O
fewer	B-Data
than	I-Data
half	I-Data
of	O
effusions	B-Process
are	O
positive	B-Data
using	O
standard	B-Process
culture	I-Process
techniques	I-Process
.	O
	
We	O
adopted	O
an	O
alternative	O
approach	O
to	O
demonstrating	O
bacteria	B-Material
in	O
OME	B-Process
,	O
using	O
a	B-Material
bacterial	I-Material
viability	I-Material
stain	I-Material
and	O
confocal	B-Material
laser	I-Material
scanning	I-Material
microscopy	I-Material
(	I-Material
CLSM	I-Material
)	I-Material
:	O
staining	B-Method
allows	O
detection	B-Process
of	O
live	B-Material
bacteria	I-Material
without	O
requiring	O
growth	B-Material
on	I-Material
culture	I-Material
,	O
while	O
CLSM	B-Method
allows	O
demonstration	O
of	O
the	B-Data
three	I-Data
-	I-Data
dimensional	I-Data
structure	I-Data
typical	O
of	O
biofilms	B-Material
.	O
	
Methods	O
Effusion	B-Material
samples	I-Material
were	O
collected	B-Process
at	O
the	O
time	O
of	O
ventilation	B-Process
tube	I-Process
insertion	I-Process
,	O
analysed	O
with	O
CLSM	B-Method
and	O
bacterial	B-Method
viability	I-Method
stain	I-Method
,	O
and	O
extended	B-Process
culture	I-Process
techniques	I-Process
performed	O
with	O
the	O
intention	O
of	O
capturing	O
all	B-Material
possible	I-Material
organisms	I-Material
.	O
	
Results	O
Sixty	B-Material
-	I-Material
two	I-Material
effusions	I-Material
(	O
42	B-Material
patients	I-Material
)	O
were	O
analysed	O
:	O
28	B-Data
(	I-Data
45.2	I-Data
%	I-Data
)	I-Data
were	O
culture	B-Data
-	I-Data
positive	I-Data
,	O
but	O
51	B-Data
(	I-Data
82.3	I-Data
%	I-Data
)	I-Data
were	O
CLSM	B-Data
-	I-Data
positive	I-Data
.	O
	
Combining	O
the	O
two	O
techniques	O
demonstrated	O
live	B-Material
bacteria	I-Material
in	O
57	B-Data
(	I-Data
91.8	I-Data
%	I-Data
)	I-Data
samples	O
.	O
	
Using	O
CLSM	B-Method
,	O
bacteria	B-Material
exhibited	O
biofilm	B-Data
morphology	I-Data
in	O
25	B-Material
effusions	I-Material
and	O
were	O
planktonic	B-Process
in	O
26	B-Data
;	O
the	B-Data
proportion	I-Data
of	O
samples	B-Material
exhibiting	O
biofilm	B-Data
morphology	I-Data
was	O
similar	O
in	O
the	B-Material
culture	I-Material
-	I-Material
positive	I-Material
and	I-Material
culture	I-Material
-	I-Material
negative	I-Material
groups	I-Material
(	O
50.0	B-Data
%	I-Data
and	I-Data
48.3	I-Data
%	I-Data
,	O
respectively	O
)	O
.	O
	
Biofilm	B-Material
samples	I-Material
contained	O
an	B-Data
average	I-Data
of	I-Data
1.7	I-Data
different	B-Material
bacterial	I-Material
isolates	I-Material
and	O
planktonic	B-Material
samples	I-Material
2.0	I-Material
,	O
with	O
the	B-Material
commonest	I-Material
bacteria	I-Material
identified	O
being	O
coagulase	B-Material
-	I-Material
negative	I-Material
staphylococci	I-Material
.	O
	
Conclusion	O
Live	B-Material
bacteria	I-Material
are	O
present	O
in	O
most	B-Process
effusions	I-Process
,	O
strongly	O
suggesting	O
that	O
bacteria	B-Material
and	O
biofilms	B-Material
are	O
important	O
in	O
the	B-Process
aetiopathogenesis	I-Process
of	I-Process
OME	I-Process
.	O
	
-DOCSTART-	
	
Mitochondrial	B-Material
aminoacyl	I-Material
-	I-Material
	
tRNA	I-Material
synthetases	I-Material
(	I-Material
aaRSs	I-Material
)	I-Material
are	O
essential	B-Material
enzymes	I-Material
in	O
protein	B-Process
synthesis	I-Process
since	O
they	O
charge	O
tRNAs	B-Material
with	O
their	B-Material
cognate	I-Material
amino	I-Material
acids	I-Material
.	O
	
Mutations	B-Process
in	O
the	B-Material
genes	I-Material
encoding	B-Process
mitochondrial	B-Material
aaRSs	I-Material
have	O
been	O
associated	O
with	O
a	B-Process
wide	I-Process
spectrum	I-Process
of	I-Process
human	I-Process
mitochondrial	I-Process
diseases	I-Process
.	O
	
Here	O
we	O
report	O
the	B-Process
identification	I-Process
of	O
pathogenic	B-Process
mutations	I-Process
(	O
a	B-Process
partial	I-Process
genomic	I-Process
deletion	I-Process
and	O
a	B-Material
highly	I-Material
conserved	I-Material
p.	I-Material
Asp325Tyr	I-Material
missense	I-Material
variant	I-Material
)	O
in	O
FARS2	B-Material
,	O
the	B-Material
gene	I-Material
encoding	I-Material
mitochondrial	I-Material
phenylalanyl	I-Material
-	I-Material
tRNA	I-Material
synthetase	I-Material
,	O
in	O
a	B-Material
patient	I-Material
with	O
early	B-Process
-	I-Process
onset	I-Process
epilepsy	I-Process
and	O
isolated	B-Process
complex	I-Process
IV	I-Process
deficiency	I-Process
in	O
muscle	B-Material
.	O
	
The	B-Data
biochemical	I-Data
defect	I-Data
was	O
expressed	O
in	O
myoblasts	B-Material
but	O
not	O
in	O
fibroblasts	B-Material
and	O
associated	O
with	O
decreased	B-Data
steady	I-Data
state	I-Data
levels	I-Data
of	O
COXI	B-Material
and	I-Material
COXII	I-Material
protein	I-Material
and	O
reduced	B-Data
steady	I-Data
state	I-Data
levels	I-Data
of	O
the	B-Material
mt	I-Material
-	I-Material
tRNAPhe	I-Material
transcript	I-Material
.	O
	
Functional	O
analysis	O
of	O
the	B-Material
recombinant	I-Material
mutant	I-Material
p.	I-Material
Asp325Tyr	I-Material
	
FARS2	I-Material
	
protein	I-Material
showed	O
an	O
inability	O
to	O
bind	B-Process
ATP	B-Material
and	O
consequently	O
undetectable	B-Process
aminoacylation	I-Process
activity	I-Process
using	O
either	B-Material
bacterial	I-Material
tRNA	I-Material
or	I-Material
human	I-Material
mt	I-Material
-	I-Material
tRNAPhe	I-Material
as	O
substrates	B-Material
.	O
	
Lentiviral	B-Process
transduction	I-Process
of	O
cells	B-Material
with	O
wildtype	B-Data
FARS2	I-Data
restored	I-Data
complex	I-Data
IV	I-Data
protein	I-Data
levels	I-Data
,	O
confirming	O
that	O
the	B-Process
p	I-Process
.	I-Process
	
Asp325Tyr	I-Process
mutation	I-Process
is	O
pathogenic	B-Process
,	O
causing	O
respiratory	B-Process
chain	I-Process
deficiency	I-Process
and	O
neurological	B-Data
deficits	I-Data
on	O
account	O
of	O
defective	B-Process
aminoacylation	I-Process
of	O
mt	B-Material
-	I-Material
tRNAPhe	I-Material
.	O
	
Highlights	O
•	O
	
The	B-Data
tissue	I-Data
specific	I-Data
variation	I-Data
in	O
presentation	O
of	O
aaRS	B-Process
mutations	I-Process
is	O
discussed	O
.	O
	
•	O
	
A	O
further	O
clinical	O
presentation	O
of	O
a	B-Data
FARS2	I-Data
defect	I-Data
.	O
	
•	O
	
Molecular	B-Process
mechanism	I-Process
of	O
FARS2	B-Data
defect	I-Data
is	O
characterised	O
in	B-Method
vitro	I-Method
.	O
	
-DOCSTART-	
	
Over	O
20years	O
ago	O
single	B-Process
clonal	I-Process
deletions	I-Process
were	O
the	B-Process
first	I-Process
mitochondrial	I-Process
DNA	I-Process
(	I-Process
mtDNA	I-Process
)	I-Process
genetic	I-Process
defects	I-Process
described	O
in	O
association	O
with	O
human	B-Process
disease	I-Process
.	O
	
Since	O
then	O
very	B-Data
large	I-Data
numbers	I-Data
of	O
children	B-Material
and	O
adults	B-Material
harbouring	B-Process
such	O
deletions	B-Process
have	O
been	O
described	O
and	O
it	O
is	O
clear	O
they	O
are	O
an	O
important	O
cause	O
of	O
human	B-Process
mitochondrial	I-Process
disease	I-Process
.	O
	
However	O
,	O
there	O
still	O
remain	O
many	O
important	O
challenges	O
in	O
relation	O
to	O
our	O
understanding	O
of	O
mechanisms	B-Process
leading	O
to	O
deletion	B-Process
formation	I-Process
and	O
propagation	B-Process
and	O
in	O
relation	O
to	O
the	B-Data
factors	I-Data
determining	O
the	B-Material
complex	I-Material
and	O
varying	O
relationship	O
between	O
genotype	B-Data
and	I-Data
clinical	I-Data
phenotype	I-Data
.	O
	
Although	O
multidisciplinary	B-Process
team	I-Process
care	I-Process
is	O
essential	O
and	O
can	O
improve	O
quality	B-Process
of	I-Process
life	I-Process
and	O
outcomes	B-Data
for	O
patients	B-Material
,	O
a	B-Process
definitive	I-Process
molecular	I-Process
treatment	I-Process
for	O
single	B-Process
mtDNA	I-Process
deletions	I-Process
remains	O
an	O
important	O
translational	B-Material
research	I-Material
goal	I-Material
.	O
	
Patients	B-Material
with	O
mtDNA	B-Process
deletions	I-Process
exhibit	O
a	B-Data
very	I-Data
wide	I-Data
range	I-Data
of	O
different	B-Material
clinical	I-Material
phenotypes	I-Material
with	O
marked	B-Process
variation	I-Process
in	O
age	B-Data
at	O
onset	B-Process
and	O
disease	B-Process
severity	I-Process
.	O
	
Single	B-Process
mtDNA	I-Process
deletions	I-Process
may	O
enter	O
into	O
the	B-Process
differential	I-Process
diagnosis	I-Process
of	O
many	B-Material
different	I-Material
paediatric	I-Material
and	I-Material
adult	I-Material
presentations	I-Material
across	O
a	B-Data
wide	I-Data
range	I-Data
of	O
medical	B-Material
specialties	I-Material
,	O
although	O
neurological	B-Material
presentations	I-Material
are	O
amongst	O
the	O
most	O
common	O
.	O
	
In	O
this	O
review	O
,	O
we	O
examine	O
the	B-Process
molecular	I-Process
mechanisms	I-Process
underpinning	O
mtDNA	B-Process
replication	I-Process
and	O
we	O
consider	O
the	O
hypotheses	O
proposed	O
to	O
explain	O
the	B-Process
formation	I-Process
and	I-Process
propagation	I-Process
of	O
single	B-Process
large	I-Process
-	I-Process
scale	I-Process
mtDNA	I-Process
deletions	I-Process
.	O
	
We	O
also	O
describe	O
the	B-Data
range	I-Data
of	I-Data
clinical	I-Data
features	I-Data
associated	O
with	O
single	B-Process
mtDNA	I-Process
deletions	I-Process
,	O
outline	O
a	B-Process
molecular	I-Process
diagnostic	I-Process
approach	I-Process
and	O
discuss	O
current	O
management	O
including	O
the	B-Process
role	I-Process
of	I-Process
aerobic	I-Process
and	I-Process
resistance	I-Process
exercise	I-Process
training	I-Process
programmes	I-Process
.	O
	
-DOCSTART-	
	
Understanding	O
transcriptional	B-Process
regulation	I-Process
of	O
pancreatic	B-Process
development	I-Process
is	O
required	O
to	O
advance	O
current	O
efforts	O
in	O
developing	O
beta	B-Process
cell	I-Process
replacement	I-Process
therapies	I-Process
for	O
patients	B-Material
with	I-Material
diabetes	I-Material
.	O
	
Current	O
knowledge	O
of	O
key	B-Material
transcriptional	I-Material
regulators	I-Material
has	O
predominantly	O
come	O
from	O
mouse	B-Process
studies	I-Process
,	O
with	O
rare	B-Process
,	I-Process
naturally	I-Process
occurring	I-Process
mutations	I-Process
establishing	O
their	O
relevance	O
in	O
man	O
.	O
	
This	O
study	O
used	O
a	O
combination	O
of	O
homozygosity	B-Process
analysis	I-Process
and	O
Sanger	B-Process
sequencing	I-Process
in	O
37	B-Data
consanguineous	B-Material
patients	I-Material
with	O
permanent	B-Process
neonatal	I-Process
diabetes	I-Process
to	O
search	O
for	O
homozygous	B-Process
mutations	I-Process
in	O
29	B-Data
transcription	B-Material
factor	I-Material
genes	I-Material
important	O
for	O
murine	B-Process
pancreatic	I-Process
development	I-Process
.	O
	
We	O
identified	O
homozygous	B-Process
mutations	I-Process
in	O
7	B-Data
different	B-Material
genes	I-Material
in	O
11	B-Data
unrelated	B-Material
patients	I-Material
and	O
show	O
that	O
NKX2	B-Material
-	I-Material
2	I-Material
and	O
MNX1	B-Material
are	O
etiological	B-Material
genes	I-Material
for	O
neonatal	B-Process
diabetes	I-Process
,	O
thus	O
confirming	O
their	O
key	O
role	O
in	O
development	B-Process
of	O
the	B-Material
human	I-Material
pancreas	I-Material
.	O
	
The	B-Data
similar	I-Data
phenotype	I-Data
of	O
the	B-Material
patients	I-Material
with	O
recessive	B-Process
mutations	I-Process
and	O
mice	B-Material
with	O
inactivation	B-Process
of	O
a	B-Material
transcription	I-Material
factor	I-Material
gene	I-Material
support	I-Material
there	O
being	O
common	O
steps	O
critical	O
for	O
pancreatic	B-Process
development	I-Process
and	O
validate	O
the	O
use	O
of	O
rodent	B-Material
models	I-Material
for	O
beta	B-Process
cell	I-Process
development	I-Process
.	O
	
Graphical	O
Abstract	O
Highlights	O
•	O
	
Homozygous	B-Process
mutations	I-Process
in	O
seven	B-Data
pancreatic	B-Data
transcription	I-Data
factors	I-Data
cause	O
neonatal	B-Process
diabetes	I-Process
•	O
	
Homozygous	B-Process
NKX2	I-Process
-	I-Process
2	I-Process
and	I-Process
MNX1	I-Process
mutations	I-Process
were	O
found	O
in	O
five	B-Material
patients	I-Material
•	O
Confirms	O
NKX2	B-Material
-	I-Material
2	I-Material
and	O
MNX1	B-Material
are	O
critical	O
for	O
murine	B-Process
and	I-Process
human	I-Process
pancreas	I-Process
development	I-Process
•	O
	
Similar	B-Data
phenotypes	I-Data
in	O
mouse	B-Material
and	O
man	B-Material
validate	B-Process
models	O
for	O
beta	B-Process
cell	I-Process
development	I-Process
Analyzing	O
a	B-Data
large	I-Data
collection	I-Data
of	O
consanguineous	B-Material
patients	I-Material
with	O
permanent	B-Process
neonatal	I-Process
diabetes	I-Process
,	O
Flanagan	O
et	O
al	O
.	O
performed	O
a	O
comprehensive	O
search	O
for	O
recessive	B-Process
mutations	I-Process
in	O
transcription	B-Data
factors	I-Data
known	O
to	O
be	O
critical	O
for	O
mouse	B-Process
pancreatic	I-Process
development	I-Process
.	O
	
They	O
identify	O
seven	B-Data
pancreatic	B-Data
transcription	I-Data
factors	I-Data
that	O
cause	O
neonatal	B-Process
diabetes	I-Process
,	O
including	O
NKX2	B-Material
-	I-Material
2	I-Material
and	O
MNX1	B-Material
.	O
	
-DOCSTART-	
	
The	B-Process
disruption	I-Process
of	O
large	B-Material
-	I-Material
scale	I-Material
brain	I-Material
networks	I-Material
is	O
increasingly	O
recognised	O
as	O
a	O
consequence	O
of	O
neurodegenerative	B-Process
dementias	I-Process
.	O
	
We	O
assessed	B-Process
adults	B-Material
with	O
behavioural	B-Process
variant	I-Process
frontotemporal	I-Process
dementia	I-Process
and	O
progressive	B-Process
supranuclear	I-Process
palsy	I-Process
using	O
magnetoencephalography	B-Method
during	O
an	B-Process
auditory	I-Process
oddball	I-Process
paradigm	I-Process
.	O
	
Network	B-Process
connectivity	I-Process
among	O
bilateral	B-Material
temporal	I-Material
,	I-Material
frontal	I-Material
and	I-Material
parietal	I-Material
sources	I-Material
was	O
examined	O
using	O
dynamic	B-Process
causal	I-Process
modelling	I-Process
.	O
	
We	O
found	O
evidence	O
for	O
a	B-Process
systematic	I-Process
change	I-Process
in	O
effective	B-Process
connectivity	I-Process
in	O
both	B-Process
diseases	I-Process
.	O
	
Compared	O
with	O
healthy	B-Material
subjects	I-Material
,	O
who	O
had	O
focal	B-Process
modulation	I-Process
of	O
intrahemispheric	B-Material
frontal	I-Material
-	I-Material
temporal	I-Material
connections	I-Material
,	O
the	B-Material
patient	I-Material
groups	I-Material
showed	O
abnormally	B-Material
extensive	I-Material
and	I-Material
inefficient	I-Material
networks	I-Material
.	O
	
The	B-Process
changes	I-Process
in	I-Process
connectivity	I-Process
were	O
accompanied	O
by	O
impaired	B-Process
responses	I-Process
of	O
the	B-Material
auditory	I-Material
cortex	I-Material
to	O
unexpected	B-Process
deviant	I-Process
tones	I-Process
(	I-Process
MMNm	I-Process
)	I-Process
,	O
despite	O
normal	B-Process
responses	I-Process
to	O
standard	B-Material
stimuli	I-Material
.	O
	
Together	O
,	O
these	O
results	O
suggest	O
that	O
neurodegeneration	B-Process
in	O
two	B-Data
distinct	B-Process
clinical	I-Process
syndromes	I-Process
with	O
overlapping	B-Data
profiles	I-Data
of	O
prefrontal	B-Process
atrophy	I-Process
,	O
causes	O
a	B-Data
similar	I-Data
pattern	I-Data
of	O
reorganisation	B-Process
of	O
large	B-Material
-	I-Material
scale	I-Material
networks	I-Material
.	O
	
We	O
discuss	O
this	B-Process
network	I-Process
reorganisation	I-Process
in	O
the	O
context	O
of	O
other	O
focal	B-Process
brain	I-Process
disorders	I-Process
and	O
the	B-Data
specific	I-Data
vulnerability	I-Data
of	O
functional	B-Material
brain	I-Material
networks	I-Material
to	O
neurodegenerative	B-Process
disease	I-Process
.	O
	
Highlights	O
•	O
	
We	O
compare	B-Process
two	B-Data
distinct	B-Process
neurodegenerative	I-Process
syndromes	I-Process
with	O
prefrontal	B-Process
atrophy	I-Process
.	O
	
•	O
	
We	O
show	O
both	B-Process
diseases	I-Process
impair	B-Process
the	B-Process
automatic	I-Process
detection	I-Process
of	I-Process
change	I-Process
(	I-Process
MMNm	I-Process
)	I-Process
.	O
•	O
	
Using	O
DCM	B-Method
we	O
discover	O
that	O
both	O
diseases	B-Process
lead	O
to	O
similar	B-Process
network	I-Process
reorganisation	I-Process
.	O
	
•	O
	
We	O
suggest	O
principled	B-Process
network	I-Process
reorganisation	I-Process
in	O
response	O
to	O
prefrontal	B-Process
degeneration	I-Process
.	O
	
-DOCSTART-	
	
Background	O
	
Although	O
magnetoencephalography	B-Method
(	I-Method
MEG	I-Method
)	I-Method
studies	I-Method
show	O
superior	B-Data
temporal	I-Data
gyrus	I-Data
(	I-Data
STG	I-Data
)	I-Data
auditory	I-Data
processing	I-Data
abnormalities	I-Data
in	O
schizophrenia	B-Process
at	O
50	B-Data
and	I-Data
100ms	I-Data
,	O
EEG	B-Method
and	I-Method
corticography	I-Method
studies	I-Method
suggest	O
involvement	O
of	O
additional	B-Material
brain	I-Material
areas	I-Material
(	I-Material
e.g.	I-Material
,	I-Material
frontal	I-Material
areas	I-Material
)	I-Material
during	O
this	B-Data
interval	I-Data
.	O
	
Study	O
goals	O
were	O
to	O
identify	O
30	B-Data
to	I-Data
130ms	I-Data
auditory	B-Process
encoding	I-Process
processes	I-Process
in	O
schizophrenia	B-Material
(	I-Material
SZ	I-Material
)	I-Material
and	O
healthy	B-Material
controls	I-Material
(	I-Material
HC	I-Material
)	I-Material
and	O
group	B-Data
differences	I-Data
throughout	O
the	B-Material
cortex	I-Material
.	O
	
Methods	O
	
The	B-Method
standard	I-Method
paired	I-Method
-	I-Method
click	I-Method
task	I-Method
was	O
administered	O
to	O
19	B-Data
SZ	B-Process
and	O
21	B-Data
HC	B-Material
subjects	I-Material
during	O
MEG	B-Method
recording	I-Method
.	O
	
Vector	B-Method
-	I-Method
based	I-Method
Spatial	I-Method
-	I-Method
temporal	I-Method
Analysis	I-Method
using	I-Method
L1-minimum	I-Method
-	I-Method
norm	I-Method
(	I-Method
VESTAL	I-Method
)	I-Method
provided	O
4D	B-Data
maps	I-Data
of	O
activity	B-Process
from	O
30	B-Data
to	I-Data
130ms	I-Data
.	O
	
Within	B-Process
-	I-Process
group	I-Process
t	I-Process
-	I-Process
tests	I-Process
compared	O
post	B-Method
-	I-Method
stimulus	I-Method
50ms	B-Data
and	I-Data
100ms	I-Data
activity	O
to	O
baseline	B-Data
.	O
	
Between	B-Process
-	I-Process
group	I-Process
t	I-Process
-	I-Process
tests	I-Process
examined	B-Process
50	B-Data
and	I-Data
100ms	I-Data
group	B-Data
differences	I-Data
.	O
	
Results	O
Bilateral	B-Process
50	B-Data
and	I-Data
100ms	I-Data
STG	B-Process
activity	I-Process
was	O
observed	O
in	O
both	B-Material
groups	I-Material
.	O
	
HC	B-Material
had	O
stronger	B-Process
bilateral	I-Process
50	B-Data
and	I-Data
100ms	I-Data
STG	B-Process
activity	I-Process
than	O
SZ	B-Process
.	O
	
In	O
addition	O
to	O
the	B-Data
STG	I-Data
group	I-Data
difference	I-Data
,	O
non	B-Process
-	I-Process
STG	I-Process
activity	I-Process
was	O
also	O
observed	O
in	O
both	B-Material
groups	I-Material
.	O
	
For	O
example	O
,	O
whereas	O
HC	B-Material
had	O
stronger	B-Process
left	I-Process
and	I-Process
right	I-Process
inferior	I-Process
frontal	I-Process
gyrus	I-Process
activity	I-Process
than	O
SZ	B-Process
,	O
SZ	B-Process
had	O
stronger	B-Process
right	I-Process
superior	I-Process
frontal	I-Process
gyrus	I-Process
and	I-Process
left	I-Process
supramarginal	I-Process
gyrus	I-Process
activity	I-Process
than	O
HC	B-Material
.	O
	
Conclusions	O
	
Less	B-Process
STG	I-Process
activity	I-Process
was	O
observed	O
in	O
SZ	B-Material
than	O
HC	B-Material
,	O
indicating	O
encoding	B-Process
problems	I-Process
in	O
SZ	B-Material
.	O
	
Yet	O
auditory	B-Data
encoding	I-Data
abnormalities	I-Data
are	O
not	O
specific	O
to	O
STG	B-Material
,	O
as	O
group	B-Data
differences	I-Data
were	O
observed	O
in	O
frontal	B-Material
and	I-Material
SMG	I-Material
areas	I-Material
.	O
	
Thus	O
,	O
present	O
findings	O
indicate	O
that	O
individuals	B-Material
with	I-Material
SZ	I-Material
show	O
abnormalities	B-Process
in	O
multiple	B-Material
nodes	I-Material
of	O
a	B-Material
concurrently	I-Material
activated	I-Material
auditory	I-Material
network	I-Material
.	O
	
Highlights	O
	
•	O
Auditory	B-Process
encoding	I-Process
in	O
schizophrenia	B-Process
(	I-Process
SZ	I-Process
)	I-Process
and	O
healthy	B-Material
controls	I-Material
(	I-Material
HC	I-Material
)	I-Material
was	O
examined	B-Process
.	O
	
•	O
	
Distributed	B-Process
source	I-Process
localization	I-Process
provided	O
whole	B-Data
-	I-Data
brain	I-Data
measures	I-Data
from	B-Data
30	I-Data
to	I-Data
130ms	I-Data
.	O
	
•	O
	
Abnormalities	B-Process
were	O
observed	O
in	O
superior	B-Material
temporal	I-Material
gyrus	I-Material
(	I-Material
STG	I-Material
)	I-Material
auditory	I-Material
areas	I-Material
in	O
SZ	B-Process
.	O
	
•	O
	
Encoding	B-Process
abnormalities	I-Process
were	O
also	O
observed	O
in	O
frontal	B-Material
and	I-Material
supramarginal	I-Material
gyrus	I-Material
areas	I-Material
.	O
	
•	O
	
SZ	B-Process
shows	O
abnormalities	B-Process
in	O
multiple	B-Material
nodes	I-Material
of	O
a	B-Material
distributed	I-Material
auditory	I-Material
network	I-Material
.	O
	
-DOCSTART-	
	
In	O
this	O
research	O
,	O
we	O
developed	O
a	B-Method
robust	I-Method
two	I-Method
-	I-Method
layer	I-Method
classifier	I-Method
that	O
can	O
accurately	B-Process
classify	I-Process
normal	B-Material
hearing	I-Material
(	I-Material
NH	I-Material
)	I-Material
from	I-Material
hearing	I-Material
impaired	I-Material
(	I-Material
HI	I-Material
)	I-Material
infants	I-Material
with	I-Material
congenital	I-Material
sensori	I-Material
-	I-Material
neural	I-Material
hearing	I-Material
loss	I-Material
(	I-Material
SNHL	I-Material
)	I-Material
based	O
on	O
their	B-Data
Magnetic	I-Data
Resonance	I-Data
(	I-Data
MR	I-Data
)	I-Data
images	I-Data
.	O
	
Unlike	O
traditional	O
methods	O
that	O
examine	O
the	B-Data
intensity	I-Data
of	I-Data
each	I-Data
single	I-Data
voxel	I-Data
,	O
we	O
extracted	O
high	B-Data
-	I-Data
level	I-Data
features	I-Data
to	O
characterize	O
the	B-Data
structural	I-Data
MR	I-Data
images	I-Data
(	I-Data
sMRI	I-Data
)	I-Data
and	I-Data
functional	I-Data
MR	I-Data
images	I-Data
(	I-Data
fMRI	I-Data
)	I-Data
.	O
	
The	B-Method
Scale	I-Method
Invariant	I-Method
Feature	I-Method
Transform	I-Method
(	I-Method
SIFT	I-Method
)	I-Method
algorithm	I-Method
was	O
employed	O
to	O
detect	B-Process
and	O
describe	B-Process
the	B-Data
local	I-Data
features	I-Data
in	O
sMRI	B-Material
.	O
	
For	O
fMRI	B-Material
,	O
we	O
constructed	B-Process
contrast	B-Material
maps	I-Material
and	O
detected	B-Process
the	B-Material
most	I-Material
activated	I-Material
/	I-Material
de	I-Material
-	I-Material
activated	I-Material
regions	I-Material
in	O
each	B-Material
individual	I-Material
.	O
	
Based	O
on	O
those	B-Material
salient	I-Material
regions	I-Material
occurring	O
across	O
individuals	B-Material
,	O
the	B-Method
bag	I-Method
-	I-Method
of	I-Method
-	I-Method
words	I-Method
strategy	I-Method
was	O
introduced	O
to	O
vectorize	B-Process
the	B-Material
contrast	I-Material
maps	I-Material
.	O
	
We	O
then	O
used	O
a	B-Method
two	I-Method
-	I-Method
layer	I-Method
model	I-Method
to	O
integrate	B-Process
these	B-Data
two	I-Data
types	I-Data
of	I-Data
features	I-Data
together	O
.	O
	
With	O
the	B-Method
leave	I-Method
-	I-Method
one	I-Method
-	I-Method
out	I-Method
cross	I-Method
-	I-Method
validation	I-Method
approach	I-Method
,	O
this	B-Method
integrated	I-Method
model	I-Method
achieved	O
an	B-Data
AUC	I-Data
score	I-Data
of	I-Data
0.90	I-Data
.	O
	
Additionally	O
,	O
our	B-Method
algorithm	I-Method
highlighted	O
several	B-Material
important	I-Material
brain	I-Material
regions	I-Material
that	O
differentiated	B-Process
between	B-Material
NH	I-Material
and	I-Material
HI	I-Material
children	I-Material
.	O
	
Some	O
of	O
these	B-Material
regions	I-Material
,	O
e.g.	O
planum	B-Material
temporale	I-Material
and	O
angular	B-Material
gyrus	I-Material
,	O
were	O
well	B-Material
known	I-Material
auditory	I-Material
and	I-Material
visual	I-Material
language	I-Material
association	I-Material
regions	I-Material
.	O
	
Others	O
,	O
e.g.	O
the	B-Material
anterior	I-Material
cingulate	I-Material
cortex	I-Material
(	I-Material
ACC	I-Material
)	I-Material
,	O
were	O
not	O
necessarily	O
expected	O
to	O
play	O
a	O
role	O
in	O
differentiating	B-Process
HI	B-Material
from	I-Material
NH	I-Material
children	I-Material
and	O
provided	O
a	O
new	O
understanding	O
of	O
brain	B-Process
function	I-Process
and	O
of	O
the	B-Process
disorder	I-Process
itself	O
.	O
	
These	B-Material
important	I-Material
brain	I-Material
regions	I-Material
provided	O
clues	B-Data
about	O
neuroimaging	B-Process
markers	B-Data
that	O
may	O
be	O
relevant	O
to	O
the	O
future	O
use	O
of	O
functional	B-Process
neuroimaging	I-Process
to	O
guide	O
predictions	B-Data
about	O
speech	B-Process
and	I-Process
language	I-Process
outcomes	I-Process
in	O
HI	B-Material
infants	I-Material
who	I-Material
receive	I-Material
a	I-Material
cochlear	I-Material
implant	I-Material
.	O
	
This	O
type	O
of	O
prognostic	B-Data
information	I-Data
could	O
be	O
extremely	O
useful	O
and	O
is	O
currently	O
not	O
available	O
to	O
clinicians	O
by	O
any	O
other	O
means	O
.	O
	
Highlights	O
•	O
	
We	O
probe	B-Process
brain	B-Process
structural	I-Process
and	I-Process
functional	I-Process
changes	I-Process
in	O
hearing	B-Material
impaired	I-Material
(	I-Material
HI	I-Material
)	I-Material
infants	I-Material
.	O
	
•	O
	
We	O
build	O
a	B-Method
robust	I-Method
two	I-Method
-	I-Method
layer	I-Method
classifier	I-Method
that	O
integrates	B-Process
sMRI	B-Material
and	I-Material
fMRI	I-Material
data	I-Material
.	O
	
•	O
	
This	B-Method
integrated	I-Method
model	I-Method
accurately	B-Process
separates	I-Process
HI	B-Material
from	I-Material
normal	I-Material
infants	I-Material
(	O
AUC	B-Data
0.9	I-Data
)	O
.	O
	
•	O
	
Our	B-Method
method	I-Method
detects	O
important	B-Material
brain	I-Material
regions	I-Material
different	O
between	O
HI	B-Material
and	I-Material
normal	I-Material
infants	I-Material
.	O
	
•	O
	
Our	B-Method
method	I-Method
can	O
include	O
diverse	B-Material
types	I-Material
of	I-Material
data	I-Material
and	O
be	O
applied	O
to	O
other	O
diseases	B-Process
.	O
	
